In a report published Monday, Mizuho Securities USA analyst Ann Hynes reiterated a Buy rating and $81.00 price target on
CVS CaremarkCVS.
In the report, Mizuho Securities USA noted, “We reiterate our Buy rating and $81 price target after a solid 1Q. Upside in the PBM helped offset weakness in retail driven by severe winter weather and a soft flu season. Even including the weather and tough flu comparisons, operating profit trends remain robust with y/y growth and margin expansion. We believe CVS is well positioned to capture share across both operating segments through continued solid execution, and we think earnings visibility is high.”
CVS Caremark closed on Friday at $73.86.
Loading...
Loading...
CVSCVS Health Corp
$60.753.40%
Edge Rankings
Momentum
53.20
Growth
57.20
Quality
27.10
Value
44.36
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|